BAckgROunD although the therapeutic response to angiotensin II receptor blockers (arBs) is assumed impaired in patients with low-renin hypertension, data are scarce about the association between levels of plasma renin activity (Pra) before treatment and response of ambulatory blood pressure (aBP) to arBs in essential hypertension.
Blockers of the renin-angiotensin system (RAS) are thought to belong to a class of drugs that have organ protective effects beyond blood pressure lowering effects. In particular, angiotensin II receptor blockers (ARBs), which do not produce dry cough, unlike angiotensin-converting enzyme inhibitors, and are associated with good compliance, are increasingly being used to treat hypertension. 1 However, it is known that low-renin hypertension is particularly common among Africans and Asians. 2 In the Japanese population, a complex interplay between genetic predisposition and environmental influences may be related to higher frequency of low-renin hypertension. Recently, it has been found that gene polymorphisms such as the angiotensinogen gene polymorphism, AGT/T235, the human α-adducing gene polymorphism, ADD1/Trp460, the aldosterone synthase gene polymorphism, CYP11B2/T (-344) , and the G-protein β3 subunit polymorphism, GNB3/T825, which are reported to be associated with salt-sensitive hypertension, are significantly more frequent in Japanese than in Caucasians. [3] [4] [5] [6] In addition, salt intake has been reported to be high in the Japanese population. 7 The excess salt intake contributes to suppression of the RAS. 8, 9 Although the therapeutic response to ARBs is assumed to be impaired in patients with low-renin hypertension, data about this issue are scarce. Therefore, we studied the association between the levels of plasma renin activity (PRA) before treatment and the response of ambulatory blood pressure (ABP) to telmisartan in untreated Japanese patients with essential hypertension.
METhODS
We prospectively studied 11 Japanese hypertensive patients whose initial systolic blood pressure was ≥140 mm Hg and/or diastolic blood pressure was ≥90 mm Hg (3 women and 8 men, mean age: 50 ± 9 years). All patients had been outpatients of Dokkyo University Hospital, and had been newly diagnosed with essential hypertension and determined not to have secondary hypertension before entry into this study, and had not received any antihypertensive medication. We recruited consecutive patients in this study. All patients had normal renal and liver function. No patient had a history of coronary artery disease, stroke, congestive heart failure, or malignancy.
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Renin Status and Response to Telmisartan
Informed consent was obtained from all the subjects. This study was approved by the Research Ethics Committee of our institute.
After a 4-week drug-free period, telmisartan was administered orally once daily at an initial dose of 20 mg for 4 weeks. If the office blood pressure remained high (systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg), the dose was increased to 40 mg once daily for another 4 weeks. In this study, a placebo was not administered in the drug-free period. Patients were instructed to maintain their usual diet including sodium intake throughout the study.
Office blood pressure was measured twice every 4 weeks by a physician (J.M.) with a mercury sphygmomanometer in the sitting position using the right arm with an appropriate cuff size and after the patient had been sitting quietly for at least 5 min. The values of two measurements were averaged. The 24-h ABP was measured every 30 min with the use of a cuff-oscillometric device (TM-2421; A&D, Tokyo, Japan). The first measurement was performed at the end of the 4-week drug-free period and the second measurement at the end of the 8-week treatment period with telmisartan. The daytime and nighttime ABPs were defined as the mean values in the awake period between 07:00 and 21:30 and in the sleeping period between 22:00 and 06:30, respectively.
During the drug-free period, overnight-fasting blood samples for measurements of PRA levels were obtained after the patients had rested in the supine position for at least 30 min. PRA was measured with a conventional radioimmunoassay method (Plasma renin activity kit; SRL, Tokyo, Japan). To avoid cryoactivation, plasma was not chilled before renin assay. Plasma was processed at room temperature and stored completely frozen.
Frozen samples were thawed rapidly to room temperature and not chilled until they were at pH 6. 10 Data are expressed as the means ± SD. The Shapiro-Wilk test was applied to verify the distribution normality. Skewed data were transformed into naturally logarithmic values. Data were analyzed using a paired t-test, an unpaired t-test, and simple and multiple regression analyses where appropriate. According to the criteria proposed by Laragh and colleagues, 9 patients were divided into two groups of lower PRA levels (<0.65 ng/ml/h) and higher PRA levels (≥0.65 ng/ml/h). Values of P < 0.05 were considered to indicate statistical significance. Table 1 shows the patients' clinical characteristics, natural log-transformed values of PRA (log PRA) before treatment, office blood pressure, 24-h ABP data before and after treatment, and final doses of telmisartan. PRA levels before treatment ranged from 0.1 to 3.5 ng/ml/h (normal range in supine position: 0.3-2.9 ng/ml/h). Although the distribution of untransformed PRA levels was skewed (W = 0.77, P = 0.004), log-transformation of PRA levels created an approximately normal distribution (W = 0.92, P = 0.30). Therefore, logtransformed PRA values were used for analyses. According to untransformed PRA levels, six patients (cases 2, 3, 4, 6, 8, and 9) were regarded as lower PRA levels (<0.65 ng/ml/h), and the other five patients (cases 1, 5, 7, 10, and 11) as higher PRA levels (≥0.65 ng/ml/h). In this present study, hemodynamic data and their changes showed an approximately normal distribution (W = 0.86-0.98, P = 0.06-0.98).
RESuLTS
Telmisartan significantly decreased the office blood pressure and the 24-h ABP ( Table 1) . Telmisartan significantly decreased the daytime ABP by 12 ± 13 mm Hg systolic (P < 0.05) and 10 ± 9 mm Hg diastolic (P < 0.01), and the nighttime ABP by 11 ± 11 mm Hg systolic (P < 0.01) and 7 ± 10 mm Hg diastolic (P < 0.05). Telmisartan did not change the ambulatory pulse rate significantly at any time.
Reductions in the office systolic and diastolic blood pressures were significantly greater in five patients with higher PRA levels than in six patients with lower PRA levels by 28 mm Hg systolic (P < 0.01) and 21 mm Hg diastolic (P < 0.001) ( Table 2) . Reductions in the 24-h systolic and diastolic ABPs by telmisartan were significantly greater in five patients with higher PRA levels than in six patients with lower PRA levels by 18 mm Hg systolic (P < 0.001) and 11 mm Hg diastolic (P < 0.05). Reductions in the daytime systolic and diastolic ABPs were also significantly greater in five patients with higher PRA levels than in six patients with lower PRA levels by 21 mm Hg systolic (P < 0.01) and 12 mm Hg diastolic (P < 0.05). In addition, reductions in the nighttime systolic ABP were significantly greater in five patients with higher PRA levels than in six patients with lower PRA levels by 14 mm Hg (P < 0.05).
Changes in the office systolic and diastolic blood pressures were significantly correlated with log PRA (r = −0.77, P < 0.01, and r = −0.82, P < 0.01, respectively). As shown in Figure 1 , changes in the 24-h systolic and diastolic ABPs were significantly correlated with log PRA. In addition, changes in the daytime systolic and diastolic ABPs significantly correlated with log PRA (r = −0.72, P < 0.05, and r = −0.68, P < 0.05, respectively), and changes in the nighttime systolic and diastolic ABPs significantly correlated with log PRA (r = −0.83, P < 0.01, and r = −0.76, P < 0.01, respectively).
In multiple regression analysis, changes in the office diastolic blood pressure significantly correlated with log PRA (β = −0.71, P < 0.01) independently of the office diastolic blood pressure levels before treatment (β = −0.29, P = 0.18). Also in multiple regression analysis, changes in the 24-h systolic ABP significantly correlated with log PRA (β = −0.66, P < 0.01) independently of the 24-h systolic ABP levels before treatment (β = −0.39, P < 0.05); changes in the 24-h diastolic ABP significantly correlated with log PRA (β = −0.72, P < 0.01) independently of the 24-h diastolic ABP levels before treatment (β = -0.35, P = 0.07).
DIScuSSIOn
As with the angiotensin-converting enzyme inhibitors, ARBs appear to have less antihypertensive efficacy in low-renin hypertension. 11 However, less is known about the relationship between the pretreatment PRA levels and the therapeutic response to ARBs in hypertensive patients. In particular, there are scarce data in the literature regarding the relationship between the pretreatment PRA levels and the ABP response to ARBs, although ABP is a better predictor of target organ damage and the risk of adverse cardiovascular events than office measurements. 12 In the present study, reductions in the 24 h and daytime ABPs by telmisartan were significantly smaller in hypertensive patients with lower PRA levels than those with higher PRA levels, indicating that the ABP response to telmisartan could be predicted by the pretreatment PRA levels. Therefore, it is assumed that measurement of the pretreatment PRA levels would inform clinicians to select the initial drug treatment more accurately. Moreover, this would avoid the problem of empirically adding antihypertensive drugs that may not improve the efficacy of treatment.
In recent years, it has been believed that the effectiveness of antihypertensive medications is considered to be derived primarily from the blood pressure lowering effect itself rather than the characteristic actions of various classes of antihypertensive Values are shown as means ± SD and systolic value/diastolic value. *P < 0.05, **P < 0.01, ***P < 0.001, versus the corresponding value of patients with lower levels of plasma renin activity. and diastolic blood pressure after treatment with telmisartan in 11 patients with essential hypertension. Changes in the 24-h systolic and diastolic aBPs were significantly correlated with log Pra (r = -0.86, P < 0.001, and r = -0.83, P < 0.01, respectively).
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Renin Status and Response to Telmisartan drugs. [13] [14] [15] On the other hand, basic and clinical research, and some clinical trial data suggest that the RAS blockers will produce organ protection beyond that which can be explained by reductions in blood pressure. 9 On the basis of that hypothesis, it is possible and reasonable that patients with low-renin hypertension with suppressed RAS activity are less likely to derive additional benefit from the RAS blockers. However, further studies are needed to obtain conclusive information. Our study has a number of limitations. First, we studied only a small number of patients, although blood pressure was evaluated by the use of ABP monitoring. Second, we did not assess the salt intake of the subjects, although salt intake is known to have a great influence on the RAS. 8, 9 Third, PRA levels were measured after the patients had rested in the supine position, although it may be a standard to measure PRA levels in the seated posture. 9 Moreover, an 18-h incubation was not done for PRA <1.0 ng/ml/h, although the angiotensin I generation step is recommended to last 18 h for samples with PRA <1.0 ng/ ml/h, to eliminate the errors inherent in the measurement, and subtraction of immunoreactive angiotensin I in the untreated plasma (blank subtraction). 10 Lastly, as we studied only telmisartan, further study is needed to confirm whether the same results are obtained from other ARBs. However, the results of the present study seem to provide valuable information to stress to clinicians that the RAS blockers such as ARBs exert blood pressure lowering effects dependent on renin status.
In conclusion, telmisartan showed blood pressure lowering effects dependent on PRA levels before treatment in patients with essential hypertension. Reductions in the 24 h and daytime ABPs by telmisartan were significantly greater in hypertensive patients with higher PRA levels (≥0.65 ng/ml/h) than those with lower PRA levels (<0.65 ng/ml/h). Measurements of PRA levels before treatment are thought to be useful for prediction of the ABP lowering effects of telmisartan.
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